In mice with prostate cancer xenografts, adding degarelix to vascular targeted photodynamic therapy significantly inhibited tumor growth versus photodynamic therapy alone.
In plain wordsIn mice, adding degarelix to vascular targeted photodynamic therapy reduced tumor growth compared with photodynamic therapy alone.
- Peptide
- Degarelix
- Outcome
- DecreaseTumor growth
- Study
mousen: not reported in source
LNCaP-AR prostate cancer xenografts- Comparator
- Vascular targeted photodynamic therapy alone
- Outcome group
- Tumor growth · Cancer
- Studied dose
- single dose, amount not reportedAs given in this study (mouse).
Source sentences
Compared with either ADT or VTP alone, a single dose of degarelix in concert with VTP significantly inhibited tumor growth.
2 context sentences(design, population, supporting numbers)
The efficacy of the combination therapy was assessed in mice bearing LNCaP-AR or VCaP tumors.
We tested this hypothesis in mice bearing LNCaP-AR xenograft tumors by using androgen deprivation therapy (ADT), degarelix, in combination with VTP.